Calliditas Therapeutics provides business update ahead of JP Morgan

 

• Strong Q4 preliminary product revenue growth with net TARPEYO revenues of $31 – 33m for the quarter, representing significant growth over Q3.
• Preliminary Net TARPEYO revenues of $100 – 102m for 2023, representing over 170% year over year growth compared to 2022.
• Preliminary Total revenues reaching $110 – 113m for 2023, as a result of milestone payments and royalty income from the Nefecon franchise outside the US.
• Record quarter in terms of enrollments with 555 new TARPEYO prescriptions in the 4^th quarter.

https://www.biospace.com/article/releases/calliditas-therapeutics-provides-business-update-ahead-of-jp-morgan-conference/